CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors
BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O'Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a Director on the Board. Chris is a highly regarded senior executive, board member and advisor across the medical devices, life sciences and global healthcare industries. Chris built his career over 21 years at Medtronic (MDT) serving in multiple business areas and functions during an era of rapid expansion. This included senior leadership roles in the Cardiovascular and Diabetes business units, before becoming Executive Vice President and President of the Restorative Therapies Group. Chris was a member of the Medtronic Executive Committee for nine years. Chris later became CEO and President of the Waters Corporation (WAT) which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations.
Article content
Paul Mead, CEO of CorFlow, said 'Chris brings exceptional strategic and operational acumen to CorFlow at a pivotal growth phase, where the company can benefit tremendously from his experience. Chris knows exactly how high the bar is set for excellence across all functions in MedTech, both from his corporate and board experiences, and from having been on the buy side of many M&A transactions. On behalf of our board, shareholders, and employees, we're thrilled to have him on board.'
Article content
Paul added, 'I would like to take this opportunity to extend my sincere gratitude for the personal support and commitment from Rick Geoffrion over the past few years, who I am glad will remain on our Board in an independent capacity.'
Article content
Chris joins CorFlow as the company embarks on achieving ambitious Series B objectives, which include two parallel clinical trials, an FDA IDE trial to obtain marketing authorization in the United States, and a landmark randomized therapy trial in Europe. CorFlow's technology aims to be the first to both diagnose and deliver therapy for heart attack patients suffering from microvascular obstruction, with a precise system that fits into the existing workflow for interventional cardiologists. The company's first in human MOCA I study results have been presented at the recent TCT and EuroPCR scientific congresses, and preclinical findings at the European Society of Cardiology meeting. CorFlow closed a €44M Series B in late 2024 with an international venture capital syndicate, and recently added further capital for expanded clinical, R&D, and capability advancement.
Article content
Chris commented, 'I am honored to join the CorFlow team, and highly motivated by the opportunity to help address a major unmet medical need for patients suffering from microvascular obstruction. CorFlow is poised for breakthrough success with such a transformative technology set, talented CEO and team, and experienced investor group. We have all the ingredients to achieve something special.'
Article content
About CorFlow Therapeutics: Headquartered in Baar, Switzerland. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
The US labor market continues to surprise and the unemployment rate, against the odds, is falling
WASHINGTON (AP) — U.S. employers added 147,000 jobs in June as the American labor market continues to show surprising resilience despite uncertainty over President Donald Trump's economic policies. The unemployment rate ticked down to 4.1% from 4.2% in May, the Labor Department said Thursday. Hiring rose modestly from a revised 144,000 in May and beat economists expectations of fewer than 118,000 new jobs and a rise in the unemployment rate The U.S. job market has cooled considerably from red-hot days of 2021-2023 when the economy bounced back with unexpected strength from COVID-19 lockdowns and companies were desperate for workers. So far this year, employers have added an average 130,000 jobs a month, down from 168,000 in 2024 and an average 400,000 from 2021 through 2023. And, according to the data released Thursday, it's getting harder to find a new job if you lose one. But the June numbers were surprisingly strong. Healthcare jobs increased by 39,000. State governments added 47,000 workers and local governments 33,000. But the federal government lost 7,000, probably reflecting Trump's hiring freeze. Manufacturers shed 7,000 jobs. Labor Department revisions added 16,000 jobs to April and June payrolls. The number of unemployed people fell by 222,000. Average hourly wages came in cooler than forecasters expected, rising 0.2% from May and 3.7% from a year earlier. The year-over-year number is inching closer to the 3.5% year-over-year number considered consistent with the Federal Reserve's 2% inflation target. 'On net, it was a good report,'' said Sarah House, senior economist with Wells Fargo, 'But when you dig underneath, the surface it was another jobs report that didn't look quite as good as first meets the eye.'' Private companies, for instance, hired just 74,000 workers, down from 137,000 in May and the fewest since last October when hurricanes disrupted the job market. State and local governments added nearly 64,000 education jobs last month – a total that may have been inflated by seasonal quirks around the end of the school year. The U.S. labor force — the count of those working and looking for work — fell by 130,000 last month following a 625,000 drop in May. Economists expect Trump's immigration deportations — and the fear of them — to push foreign workers out of the labor force. Hiring decelerated after the Fed raised its benchmark interest rate 11 times in 2022 and 2023. But the economy did not collapse, defying widespread predictions that the higher borrowing costs would cause a recession. Companies kept hiring, just at a more modest pace. Employers are now contending with fallout from Trump's policies, especially his aggressive use of import taxes – tariffs. Mainstream economists say that tariffs raise prices for businesses and consumers alike and make the economy less efficient by reducing competition. They also invite retaliatory tariffs from other countries, hurting U.S. exporters. The erratic way that Trump has rolled out his tariffs — announcing and then suspending them, then coming up with new ones — has left businesses bewildered and hesitant to make decisions about hiring and investment. House at Wells Fargo expects monthly job growth to fall below 100,000 in the second half of the year. 'We're bracing for a much lower pace of job growth,'' she said. 'There's still a lot of policy uncertainty.'' Still, the upside surprise in June payrolls likely will encourage the Fed to continue its wait-and-see policy of leaving rates unchanged until it has a better idea of how Trump's tariffs and other policies will affect inflation and the job market. The Fed cut rates three times last year after inflation cooled but has turned cautious in 2025. "Today's results are more than positive enough to reduce expectations for Fed rate cuts in the wake of tariffs and policy chaos, at least for now,'' Carl B. Weinberg, chief economist at High Frequency Economics, wrote in a commentary. With unemployment low, most Americans enjoy job security. But as hiring has cooled over the past couple of years it's become harder for young people or those re-entering the workforce to find jobs, leading to longer job searches or longer spells of unemployment. The Labor Department said the number of discouraged workers, who believe no jobs are available for them, rose by 256,000 last month to 637,000. When he was laid off earlier this year from his job as a communications manager for a city government in the Seattle area, Derek Wing braced for the worst. 'The word I would use is: 'terrifying''' to describe the experience, he said. Lots of big local employers like Microsoft continue to cut jobs. And he'd heard horror stories of people applying for jobs and then – crickets. 'I had a couple of experiences where I would apply for a job and just feel like it was going out into the ether and never hearing back,'' he said. But Wing's fortunes turned quickly. He applied for an opening with Gesa Credit Union. 'When I saw the job, it immediately felt right,'' he said. 'I actually told my wife: 'This is the job I want.'' Six weeks later – 'superfast in this economy'' -- he had a job as a communications strategist for Gesa. The Richland, Washington, credit union had revamped its hiring process to be easier and more transparent for applicants when it was tough to find workers in the hiring boom that followed the COVID-19 pandemic. 'It was really an employee's market for a while,'' said Cheryl Adamson, Gesa's chief risk officer. 'Then the winds have shifted a little bit more in favor of the employer.''
Globe and Mail
2 hours ago
- Globe and Mail
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Year to date, REGN's shares have lost 22.9% compared with the industry 's 0.6% decline. More on REGN's MM Drug The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population. With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 alone. Lynozyfic is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM. The approval strengthens REGN's oncology portfolio. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. REGN's Efforts to Strengthen Oncology Portfolio REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024. The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025. The successful development of these oncology drugs should be a great boost for REGN. The decline in lead drug Eylea sales is a concern for REGN. Eylea sales are under pressure due to competition from Roche 's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea. REGN's Zacks Rank and Stocks to Consider REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
Pfizer PFE has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since the end of May, the stock has been trading above its 50-day simple moving average (SMA), indicating a short-term bullish trend. The 50-day SMA is a key indicator for traders and analysts, used to identify support and resistance levels. It is considered particularly important as it's the first marker of an uptrend or a downtrend. The stock has consistently traded below its 50-day average since mid-March till the end of May as it faces several headwinds, including declining sales of its COVID-19 products, U.S. Medicare Part D changes and the looming threat of patent expirations on several key drugs. However, despite the headwinds, its key drugs like Vyndaqel, Padcev, Eliquisand new and newly acquired products should continue to drive top-line growth. Its cost cuts and internal restructuring are saving costs. Let's understand the company's strengths and weaknesses to better analyze how to play the stock as it consistently trades above the 50-day SMA mark. Sales of PFE's COVID Products Declining With the end of the pandemic, sales of Pfizer's COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer's revenues from Paxlovid and Comirnaty are expected to be similar to 2024. COVID revenues may decline further in future years, depending on infection rates. PFE's New Drugs & Seagen Acquisition Drive the Top Line Though COVID revenues are declining, Pfizer's non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen (December 2023. The positive trend continued in the first quarter of 2025. Continued growth of Pfizer's diversified portfolio of drugs, particularly oncology, should support top-line growth in 2025. Pfizer's new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, position it strongly for operational growth in 2025 and beyond. Pfizer expects the 2025 to 2030 revenue CAGR to be approximately 6%. PFE Enjoys a Strong Position in Oncology Pfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen strengthened its position in oncology. Its oncology revenues are rising, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved products (oncology as well as non-oncology) like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others. Other Headwinds in 2025 Though Pfizer expects a moderate negative impact on revenues from the loss of exclusivity in 2025, the impact is expected to be significant in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. Pfizer expects an unfavorable impact of approximately $1 billion from the Medicare Part D redesign under the IRA. Higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA. In April, Pfizer said it is discontinuing the development of its GLP-1R agonist, danuglipron, which was developed as a weight loss pill. Pfizer took the decision after one of the participants in the dose-optimization studies developed a potentially drug-induced liver injury, which resolved after danuglipron was discontinued. Novo Nordisk NVO and Eli Lilly LLY currently dominate the obesity market with their GLP-1 injections. PFE's Stock Price, Estimates & Valuation Pfizer's stock has declined 1.1% so far this year against an increase of 0.8% for the industry. PFE Stock Underperforms Industry From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 8.23 forward earnings, lower than 15.05 for the industry and the stock's 5-year mean of 10.87. The stock is also much cheaper than other large drugmakers like AbbVie, Novo Nordisk, Lilly, AstraZeneca, J&J and others. PFE Stock Valuation The Zacks Consensus Estimate for earnings has remained unchanged at $3.06 per share for 2025 and $3.09 per share for 2026 over the past 30 days. PFE Estimate Movement Stay Invested in PFE Stock Pfizer faces its share of challenges, including declining sales of its COVID-19 products, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity (LOE) cliff in the 2026-2030 period, uncertainties around tariffs and a volatile macro environment. However, with COVID-related uncertainties diminishing, its revenue volatility is declining. Pfizer's key drugs like Vyndaqel, Padcev and Eliquis and new and newly acquired products should continue to drive top-line growth. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer's significant cost reduction and efforts to improve R&D productivity measures should drive profit growth. Though Pfizer does not expect strong top-line growth over the next three years due to the LOEs, it expects EPS growth. Pfizer's dividend yield stands at around 7%, which is impressive. Investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as it appears to have significant upside potential. Its new drugs and a robust pipeline may help navigate the upcoming LOE period. It will be a great pick for value investors, considering its cheap valuation, and for income investors due to its sky-high dividend yield. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report
